Collplant Biotechnologies Ltd AD Up 2.17% To $6.58 After Earnings

Collplant Biotechnologies Ltd AD (CLGN) said before open Thursday that it broke even in quarter two 2023.

In the same quarter a year ago, the company lost $0.36 per share on revenue of $66 thousand.

The stock is up 2.17% to $6.58 after the report.

Collplant Biotechnologies Ltd AD's profit margins maintained as both earnings and revenue declined at the same pace.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Collplant Biotechnologies Ltd AD a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 44. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The company's revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing.